Skip to content

Withdrawal treatment in medication overuse headache

Comparison between Celecoxib and Prednisolone in bridge stage therapy following medication overuse headache

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013061211560N6
Enrollment
120
Registered
2013-09-10
Start date
2011-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Overuse Headache. Drug-induced headache

Interventions

Intervention 1: Prednisone as a 75mg, 50 mg, 30 mg, 25 mg and 10 mg/day (every 3 days). Intervention 2: Celexcib as a 100mg three times, twice and one time/day (every 5 days).
Treatment - Drugs
Prednisone as a 75mg, 50 mg, 30 mg, 25 mg and 10 mg/day (every 3 days)
Celexcib as a 100mg three times, twice and one time/day (every 5 days)

Sponsors

Deputy of Research,Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 18-65 years old; headache more than 15 days per month; regular using of two drugs or more for symptomatic therapy more than 3 month; progressive headache; no underlying disease; no pregnancy. Exclusion criteria: no follow up and stopping of using drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Headache time. Timepoint: Start of treatment, 2 weeks following start of treatment. Method of measurement: Hour.;Headache. Timepoint: Start of treatment, 2 weeks following start of treatment. Method of measurement: Visual Analogue Scale.;Headache days. Timepoint: Start of treatment, 2weeks following start of treatment. Method of measurement: Days.

Secondary

MeasureTime frame
Drug adverse reaction. Timepoint: Start of treatment, 2 weeks following start of treatment. Method of measurement: Hstory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Taghvaii Zahmat kesh

Sina Hospital, Tehran University of Medical Sciences

elahetaghvaii@tums.ac.ir+98 21 6312 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026